Business Description
TRex Bio is a biopharmaceutical company focused on developing medicines that harness the body's natural immune-regulating cells, known as regulatory T cells, to treat autoimmune and inflammatory conditions. The company uses a proprietary discovery platform that combines human tissue data, gene expression mapping, and laboratory modeling to identify and validate drug targets with greater biological precision. Its pipeline includes several investigational therapies targeting conditions such as inflammatory bowel disease and lupus, with one program developed in partnership with an external collaborator. Founded in 2018 and headquartered in South San Francisco, TRex Bio operates across both domestic and international markets.
